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Background: Neutrophil gelatinase-associated lipocalin (NGAL) is a useful biomarker for the early prediction of renal
diseases. NGAL may exist as monomer, dimer and/or NGAL/MMP-9 complex forms in humans. In this study, the
existence of various forms of NGAL in urine (uNGAL) was determined and whether these forms are related to the
different urinary diseases found in dogs is further discussed.
Results: Eighty-one urine samples from dogs with different forms of renal disease (41), pyuria (19) and a number
of non-renal related diseases (10), as well as healthy dogs (11), were collected. uNGAL concentrations and their
molecular forms in dogs were measured by ELISA and Western blot analysis, respectively. The uNGAL concentrations
of dogs with pyuria (median: 15.35 ng/mL) were significantly higher than those of the healthy control animals
(median: 3.92 ng/mL) (p < 0.01), but lower than those of dogs with renal diseases (median: 23.77 ng/mL). Each
NGAL molecular form could be detected in dog urine. In particular, monomer was detected more frequently in
patients with renal disease than those with non-renal diseases; while the dimer form appeared in a significantly
higher percentage of cases with pyuria compared to those without pyuria. The NGAL/MMP-9 complex was found
to exist not only in the patients with cystitis, but also in the cases with renal injury.
Conclusion: Different molecular forms of uNGAL can indicate different origins of the urinary abnormalities. Determining
the molecular forms of uNGAL present in diseased dogs may provide clinical workers with a tool that will help the early
and more precise detection of different urinary diseases.
Keywords: Azotemia, Biomarker, Cystitis, NGALBackground
Neutrophil gelatinase-associated lipocalin (NGAL) is a
glycoprotein belonging to the lipocalin family with a size
of about 25 kDa [1]. NGAL is not only expressed by
neutrophils but also expressed in a variety of other tis-
sues, including non-neoplastic breast tissue, kidneys,
liver, lungs, intestines, bone marrow, adipose tissue and
macrophages [2-5]. Normally, renal NGAL is filtered via
the glomerulus and then reabsorbed by the proximal
tubular epithelial cells. However, when the kidneys are* Correspondence: yajanelee@ntu.edu.tw
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unless otherwise stated.damaged, there is increased NGAL expression together
with decreased NGAL re-absorption and these contrib-
ute to an increased NGAL concentration in both serum
and urine [6-8].
Changes in concentrations of NGAL in both serum
and urine have been proved to immediately reflect renal
injury as early as 2 h after cardiac surgery [9,10]. More-
over, these biomarkers are also considered to be good
prognostic indicators for acute kidney injury (AKI)
[11-14] and various forms of chronic kidney diseases
[15,16]. Similarly, in veterinary studies, uNGAL has been
proved to be an important biomarker for dogs with dif-
ferent urinary diseases [10,17-20].
It has been noticed that various NGAL protein forms
can be detected when they are differentiated using. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic illustration of the case groupings used in
this study. A total of 81 samples were analyzed. Based on the
patients’ clinical parameters, the samples were classified into a
number of different groups. These were the RF group with azotemia,
the RF-PYU group with azotemia and pyuria, the PYU group with
pyuria but without azotemia, the non-RP group with diseases unrelated
to azotemia and pyuria; the AKI groups with acute kidney disease and
the CKD group with chronic kidney disease.
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esis (SDS-PAGE) followed by Western blotting. NGAL
monomer, with a size of approximately 25 kDa, can be
observed using reducing SDS-PAGE, while NGAL dimer,
with a size of approximately 45 kDa, can be detected
using non-reducing SDS-PAGE [21,22]. Furthermore, a
heterodimer complex with a size of 135 kDa, where
NGAL is covalently conjugated with MMP-9, can also
be detected [23]. Previous studies have shown that
NGAL, when secreted from neutrophils, occurs as both
the 45 kDa dimer and as the 25 kDa monomer, but with
the dimer being the major NGAL form. Nevertheless,
under cytokine stimulation, the 25 kDa monomer form
of NGAL was found to be the predominantly expressed
form in the human kidney epithelial cells [24].
An increase in certain forms of uNGAL might suggest
the occurrence of different diseases. For instance, in-
creased amounts of the monomeric form of NGAL have
been found in urine of human patients with AKI after
cardiac surgery, while a higher proportion of NGAL
dimer has been noted in human patients with urinary
tract inflammation (UTI) [24]. Moreover, the NGAL/
MMP- 9 complex have also been detected in a variety of
tumor tissues and when humans are suffering from
acute cystitis [24-26].
Despite the fact that the origin of the various molecu-
lar forms of uNGAL has investigated, the majority of
samples analyzed as part of that series were from pa-
tients with surgery induced AKI and only five UTI cases
were included in this human medical study [27]. At
present, little is known about the correlation between
different forms of NGAL and naturally occurring renal
disease and UTI. Moreover the different molecular
forms of the urinary NGAL have never been investi-
gated in dogs. Hence, in order to obtain a better un-
derstanding of the expression profile of uNGAL and the
potential clinical application of urine NGAL in dogs, the
aim of the present study was to determine the presence
and origin of the various different molecular forms of
UNGAL together with the various factors that affect the
formation of these NGAL forms, as well as concentrations
of NGAL in dog urine.
Methods
Patients and sample collection
Samples were prospectively obtained, as part of routine
diagnostics, from clinical cases admitted to the National
Chung Hsing University Veterinary Teaching Hospital
from September 2012 to March 2013 (IACUC approval
No: 102-63). Urine samples came from catheterized and
cystocentensis, and by natural voiding. The haemato-
logical parameters collected included haematocrit, white
blood cell (WBC) count, neutrophil counts (segment,
band) and serum/plasma biochemistry, which consistedof Blood Urine Nitrogen (BUN), creatinine, urine dip-
stick test (urine glucose, bilirubin, ketones, urine specific
gravity, pH, urine protein, hemoglobin/blood, urine uro-
bilinogen), White blood cells (WBC) count, and urine
sediment level including red blood cells (RBCs) and
WBCs in the high power field (HPF). Medical history
and diagnosis were also recorded.
Case grouping criteria
The samples were divided into five groups (Figure 1).
Healthy animals that were being vaccinated or undergo-
ing health checks that had no medical history of disease,
that lacked any clinical signs related to any disease, and
that had BUN and creatinine levels within the normal
range (BUN <8.9 mmol/L, creatinine <133 μmol/L), as well
as urine leukocytes <25/μL by dipstick and WBC in urine
sediment <5/HPF; these were classified as the healthy con-
trol group. The pyuria group consisted of cases without
azotemia (BUN <8.9 mmol/L and creatinine <133 μmol/L)
but with a WBC count >5/HPF in the urine sediment.
The dogs with clinical signs related to uremia and with a
serum/plasma biochemistry showing BUN> 8.9 mmol/L,
creatinine > 133 μmol/L were categorized as the renal fail-
ure (RF) group among the patients. Furthermore, on basis
of the urine test results, the cases with or without pyuria
criteria were categorized into the RF-PYU group, and the
RF group, respectively. Finally, according to the patient’s
history (less than 14 days) and diagnostic images (enlarged
or small kidneys), the RF cases were divided into the AKI
and chronic kidney disease (CKD) groups. The remaining
ten cases that were without any urinary diseases (excluded
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classified as the non-RP group (non-RF-PYU), which in-
cluded two cases of protein losing enteropathy, two cases
of gastritis, two cases with hepatic disorders, one case of
enteritis, one case of portal shunt, one case of bone frac-
ture and one case of intervertebral disk disease.
MMP 9 antibody preparation
For detection of canine MMP-9, mouse polyclonal anti-
body was generated. Initially, the canine MMP-9 coding
region was amplified from the testicular tissue of a male
dog that had been admitted to National Chung Hsing
University Veterinary Teaching Hospital for neutering.
Total RNA was extracted using an RNeasy® kit (Qiagen)
and 2 μg of total RNA was then used as template for the
generation of cDNA using a Superscript III Supermix kit
(Invitrogen). The partial sequence of MMP-9 was ampli-
fied by PCR using the primer set (forward 5′-AACA
TATGGCCATCGCGGAGATCAGGAACTAC-3′ and
reverse primer 5′-AACTCGAGGCACTGCAAAATGT
CAAAG-3′); these primers amplified nucleotides 1580-
2131 of the MMP-9 gene. The conditions used for the
thermal cycling were an initial denaturing at 98°C for 30
seconds, and then 35 cycles of 98°C for 10 seconds
(denaturing), 62°C for 30 seconds (annealing), 72°C for
30 seconds (extension); this was followed by a final ex-
tension at 72°C for 10 minutes. The resulting PCR frag-
ment (550 base pairs) was then digested with Nde I and
Xho I (the sequences of which had been introduced by
primers, as indicated by the underlining) and cloned into
the prokaryotic expression vector pET24a, which had
been linealized with the same enzymes. A clone with an
insertion of the MMP-9 sequence (plasmid MMP-9/
pET24) was confirmed by restriction enzyme pattern ini-
tially and then verified by automated sequencing.
The plasmid MMP-9/pET24 was then transformed
into E. coli (strain BL21 pLySs) and expression of the
partial MMP-9 protein, which is fused with a 6-histidine
tag, was induced by 0.8 mM of IPTG at 25°C overnight.
Recombinant MMP-9 protein was purified using chelat-
ing Sepharose Fast Flow (GE Healthcare) and the iden-
tity of protein was confirmed by Western blot analysis
using antibody against the histidine tag following the
method described in a previous report [28].
Polyclonal antibodies against MMP-9 were produced
using specific-pathogen-free (SPF) mice and the protocol
was approved by the Institutional Animal Care and
Use Committee of National University of Chung-Hsing
University, permit number: 100-66. Two female BALB/c
mice, purchased from National laboratory animal canter
in Taiwan were kept in the same cage. Mice were initially
immunized with 50 μg of the MMP-9 recombinant pro-
tein mixed with complete Freund’s adjuvant (Sigma) per
mouse and this was followed by two boosters of the samedose at two-week interval. Plasma was then obtained from
the immunized mice and stored at -20°C until use.
Western blot analysis
For the reducing SDS-PAGE, pre-clarified (centrifuga-
tion at 3000 rpm for 5 min at 4°C) urine samples were
mixed with 5× SDS sample buffer (0.31 M Tris, 10%
SDS, 50% glycerol) and this was followed by boiling for
5 min before resolving the proteins present in the urine
by 10 or 12% SDS-PAGE. For the non-reducing SDS-
PAGE, the protein mix was directly loaded into gel with-
out boiling. Subsequently, the gel was electrophoretically
transferred to nitrocellulose membrane. The Western
blot analysis followed the procedures described in a pre-
vious report [10]. Briefly, the filter was blocked using
PBS containing 0.1% Tween-20 (PBST) and 5% skimmed
milk for 1 hour at room temperature and then the filters
were incubated with diluted first antibody (Ab), namely
1:800 diluted rabbit anti-canine NGAL Ab or 1:100 diluted
mouse anti- canine MMP-9 polyclonal Ab. After incuba-
tion at 4°C for overnight, the membrane was washed thor-
oughly in PBST. This was then followed by adding 1:
10000 diluted horseradish peroxidase (HRP)-conjugated
secondary antibody in PBST with 2% dried milk at room
temperature for 1 hour. After washing with PBST, the
membrane was developed using an enzyme-linked chemi-
luminescence system (GE Healthcare Bio-science Corp)
and scanned on a Kodak Image Station 2000R.
Based on the existence of the distinct molecular forms
of NGAL, regardless of whether there were other
uNGAL forms present at the same time, all the cases
were grouped into the following categories: monomer (+)
and monomer (-) groups; dimer (+) and dimer (-) groups;
NGAL/MMP-9 complex (+) and NGAL/MMP-9 com-
plex (–) groups.
Measurement of urine NGAL concentrations by ELISA
The concentration of NGAL in urine was determined by
sandwich ELISA as described in our previous study [10].
Briefly, the capture antibody (1:800 diluted rabbit anti-
canine NGAL antibody) was coated. After blocking, all
the test samples were diluted 20-fold with PBST contain-
ing 5% dried milk. Recombinant NGAL proteins at
known concentrations were used as positive controls to
calibrate the system. Samples were individually added to
each well and incubated at 4°C overnight. After washing
with PBST, 1:3000 diluted mouse anti-canine NGAL
antibody (the detector antibody) was added to the well
followed by incubation at 37°C for 1 hour. Subsequently,
5,000 fold diluted HRP conjugated goat anti-mouse IgG
antibody was added to the wells and incubated for 1 hour.
The result was visualized using a tetramethylbenzidine
(TMB) substrate kit (Clinical Science Laboratory, Inc)
and the optical density (OD) was read using a microplate
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times independently. The OD values of the triplicates were
averaged. Samples with an OD value three-fold higher
than the negative control serum were considered NGAL-
positive.
Statistical analysis
SPSS 16.0 for Windows was used for data analysis.
Initially, the variable dataset was assessed using the
Shapiro-Wilk test. Normally distributed data are pre-
sented as mean (standard error). An analysis of variance
(ANOVA), together with the Student’s t test, was applied
to compare means. Non-normally distributed data are
presented as median and interquartile range (IQR). The
Mann-Whitney U test and Kruskal-Wallis Test were
used for nonparametric analysis. The LSD test and
Mann-Whitney U were used as post hoc assessments for
the normally distributed and non-normally distributed
data, respectively. Categorical data are presented as pro-
portions. The χ2 test or the Fisher’s Exact Test was uti-
lized to compare the datasets. Values where p < 0.05 are
considered to be significantly different.
Results
In this study, the uNGAL concentrations of the 81 dogs
were measured and categorized in different groups
(Figure 1). The cases without any urinary diseases
(excluding the RF and UTI groupings), but with
other diseases, were classified as the non-RP group
(non-RF-PYU), which included two cases of protein los-
ing enteropathy, two cases of gastritis, two cases with
hepatic disorders, one case of enteritis, one case of portal
shunt, one case of bone fracture and one case of interver-
tebral disk disease. Samples from the RF group (AKI and
CKD) had the highest concentration of uNGAL, followed
in descending order by RF-PYU, PYU, non-RP and the
healthy control group. Comparing the uNGAL concen-
trations between groups, despite the fact that there was
no significant difference between the non-RP and control
group, significant differences were observed between
these two groups and the other groups. For instance, theTable 1 Comparative analysis of the urinary NGAL concentrat
Parameter Control (n = 11) AKI (n = 16) CKD (
uNGAL (ng/mL) 3.92a (9.05) 37.90b (56.08) 18.96b
Age (year) 6 (4) 8 (4.75) 7 (1
BUN (mmol/L) 4.6a (3.9) 49.3d (53.6) 15.4b
Creatinine (μmol/L) 97.3a (44.2) 291.7c (580.8) 194.5b
Urine Sp. Gr. 1.02 (0.01) 1.019 (0.01) 1.014
Analysis of variance among and between the groups was performed by Kruskal-Wall
Different superscript letters (a. b, c) represents a significant difference between two
azotemia with pyuria; PYU: pyuria without azotemia; non-RP: diseases without any re
Urine Sp. Gr.: urine specific gravity.uNGAL concentrations of RF, RF-PYU, PYU, non-RP
were significantly higher than those of the non-RP and
the healthy control groups. Although the uNGAL level in
the RF group (both AKI and CKD) was higher than con-
trol and non-RP, there was no significant difference in
uNGAL level among all the groups (AKI, CKD, RF-PYU
and PYU) in relation to different urinary diseases
(Table 1). The AKI and RF-PYU groups showed signifi-
cantly higher serum creatinine levels than CKD group,
however, the serum creatinine levels of the Non-RP, con-
trol and PYU groups were lower than the CKD group
(Table 1).
Canine MMP9 antibody was successfully produced
(Figure 2). As shown in Figure 3A, three different forms
of uNGAL were successfully detected in all the urine
samples collected from patients (Figure 3). The two
forms with smaller molecular weight, namely ~25 kDa
and ~50 kDa, represent the monomeric and dimeric
forms of NGAL, respectively. The remaining higher mo-
lecular weight form of the NGAL related protein, with a
molecular weight over 130 kDa, was then identified as
the NGAL/MMP-9 complex by Western blot analysis
using antibodies against canine-MMP-9 (Figure 3B).
The presence of monomeric and dimeric uNGAL was
noted in 47 cases, and 20 cases, respectively (Table 2).
Compared to the cases without uNGAL monomer, the
dogs with monomeric uNGAL were found to have
higher levels concentrations of uNGAL, BUN, creatinine,
blood leukocytes including WBCs, segmented neutro-
phils and neutrophils (p <0.01) (Table 2); nevertheless,
the increase in WBC numbers in the urine was not sig-
nificant among the dogs where monomeric uNGAL was
present (p = 0.097). Dimeric uNGAL was detected in 20
dogs. The only significantly different parameter between
the dogs with dimer uNGAL and without dimer uNGAL
was urine WBC numbers (p <0.01).
In addition, 55/81 samples were found to contain the
NGAL/MMP-9 complex (Table 3). Dogs that had the
urine NGAL/MMP-9 complex present were found to
have significantly higher BUN, creatinine, urinary red
blood cells and urinary white blood cells, but had aions among the different groups
n = 8) RF-PYU (n = 17) PYU (n = 19) Non-RP (n = 10)
(11.19) 18.97b (70.32) 15.35b (27.663) 9.22a (10.36)
0) 5 (4) 5.5 (2.25) 4.5 (4.5)
(13.1) 32.5c (20.5) 7.5a (4.3) 6.0a (4.11)
(92.8) 291.7c (154.7) 106.1a (44.2) 70.7a (59.2)
(0.02) 1.015 (0.01) 1.015 (0.01) 1.015 (0)
is Test and Mann-Whitney T test individually and the median (IQR) is presented.
groups (p < 0.05). AKI: acute kidney injury; CKD: chronic kidney disease; RF-PYU:
lation of azotemia and pyuria.
Figure 2 Preparation of recombinant MMP-9 protein for mouse
immunization. (A) Partial MMP-9 coding region (nucleotide1580-2131)
was amplified by RT-PCR using cDNA (lane +) generated from RNA of
canine testis. (B) The recombinant MMP-9 with expected size of
22 kilo-Dalton (kDa) was expressed in E. coli and purified by metal
affinity chromatography (lane 1).
Table 2 Parameters with significant differences between
the groups with and without monomeric uNGAL present
Parameter Monomer(+)
(n = 47)
Monomer(-)
(n = 34)
p*
uNGAL (ng/mL) 47.39 (23.74) 8.328 (16.16) 0.001
BUN (mmol/L) 21.42 (34.99) 19.76 (10.98) 0.001
Creatinine (μmol/L) 194.48 (194.48) 123.76 (68.95) 0.007
WBC (/μL) 20200 (16100) 11300 (6775) <0.001
Segmented neutrophil (/μL) 17072 (13000) 8075 (6433) <0.001
Neutrophil (/μL) 17460 (13500) 8316 (6540.75) <0.001
The Mann-Whitney T test was used and the median (IQR) is presented. *p < 0.05
indicates a significant difference. Monomer (+): with monomeric NGAL;
monomer (-): without monomeric NGAL.
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NGAL/MMP-9 in the urine (p <0.05) (Table 3). How-
ever, no significant difference was found when the blood
leukocyte counts of the two groups with and without
NGAL/MMP-9 complex were compared.
Based on the occurrence of renal failure, the whole study
population (n = 81) could be divided into a RF (all) group
(n = 41), and a non-renal failure group (n = 40), with the
latter including the healthy Control, PYU and non-RP
groups (Figure 1). Interestingly, a significantly higher fre-
quency of monomer and NGAL/MMP-9 complex together
was present in the urine of cases in the RF (all) group com-
pared to the group without renal failure (Table 4).Figure 3 Western blot analysis of the various NGAL molecular forms.
(enteritis, lane 3), CKD (lane 4), and control (lane 6) groups were resolved u
polyclonal antibodies against canine NGAL (A), or canine MMP-9 (B). Three
recognized by the anti-NGAL antibodies; the protein with highest molecula
and C indicate the monomeric NGAL, the dimeric NGAL, and the NGAL/MMWhen the presence or absence of pyuria was consid-
ered, the whole study population (n = 81) could be di-
vided into a PYU (all) groups (n = 36), which includes
the PYU and RF-PYU groups (Figure 1), and the Pyuria (-)
group (n = 45), which includes the control, RF and non-RP
groups. When the presence of the various molecular forms
of uNGAL were compared between the PYU (all) and
Pyuria (-) groups, the result indicated that only dimeric
NGAL was present at higher frequency across the PYU
group (p = 0.002). Furthermore, there was no significant
difference in terms of NGAL molecular forms between
the RF and PYU groups. However, among other groups,
the cases within both the RF and PYU groups had a sig-
nificantly higher proportion of cases with the uNGAL/
MMP-9 complex present (Table 4).
Discussion
In this study, anti-canine NGAL and anti-canine MMP-
9 polyclonal antibodies were produced in our laboratory
and these were successfully used to detect the variousUrine samples representing the PYU (lane 1, 5), AKI (lane 2), non-RP
sing non-reducing SDS-PAGE followed by Western blot analysis using
different NGAL related proteins, as indicated by the arrowheads, were
r weight could also be detected using the anti-MMP-9 antibodies. M, D,
P-9 complex, respectively.
Table 3 Parameters with significant differences between
the groups with or without urine NGAL NGAL/MMP-9
complex present
Parameter Complex (+)
(n = 55)
Complex (−)
(n = 26)
*p
uNGAL (ng/mL) 16.973 (33.52) 18.697 (17.07) 0.022
BUN (mmol/L) 20.71 (34.99) 7.5 (6.6) <0.001
Creatinine (μmol/L) 185.64 (203.32) 114.92 (53.04) 0.001
Urine RBC (/μL) 150 (225) 0 (31.25) <0.001
Urine WBC (/μL) 25 (500) 0 (100) 0.018
The Mann-Whitney T test was used and the median (IQR) is presented. *p <0.05
indicates a significant difference. Complex (+): with NGAL/MMP9 complex;
Complex (-): without NGAL/MMP9 complex.
BUN: blood urine nitrogen; RBC: Red blood cell; WBC: white blood cell; NGAL:
neutrophil gelatinase-associated lipocalin; MMP9: Matrix metallopeptidase 9.
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Western blotting using non-reducing conditions. Similar
to human patients [21,23], uNGAL in dogs has three
forms, namely a 25 kDa monomer, a 50 kDa dimer and
a 130 kDa NGAL/MMP-9 heterodimer complex. Over-
all, the presence of monomer uNGAL was found to be
significantly associated with abnormal levels of serum
BUN and creatinine. Furthermore, the proportion of
cases with uNGAL monomer was also significantly dif-
ferent between RF negative and the RF all groups; thus
the increase of uNGAL monomer appears to be related
to kidney injury, which indirectly indicates that canine
uNGAL monomer is likely to have originated from the
kidneys. However, the cases with monomeric uNGAL
were found to be associated with an increased presence
of urine blood leukocytes in this study. In humans,Table 4 Comparative analysis of the proportions of cases
with the three individual molecular forms of uNGAL
across the different groups
Monomer Dimer NGAL/MMP-9 (+)
RF(all) 73.1% (30/41) 26.8% (11/41) 50% (20/40)
RF- 42.5% (17/40) 22.5% (9/40) 85.3% (35/41)
p 0.005* 0.651 0.001*
PYU(all) 69.4% (25/36) 41.2% (15/36) 77.8% (28/36)
PYU- 48.9% (22/45) 11.1% (5/45) 60% (27/45)
p 0.063 0.002* 0.89
RF 75% (18/24) 20.8% (5/24) 79.1% (19/24)
PYU 68.4% (13/19) 47.4% (9/19) 63.6% (12/19)
p 0.633 0.065 0.245
RF-PYU 70.1% (12/17) 35.3% (6/17) 94.1% (16/17)
PYU 68.4% (13/19) 47.4% (9/19) 63.6% (12/19)
p 0.888 0.463 0.044*
The data was analyzed by χ2 test. *indicates a significant difference - found
(p<.05. RF (all) azotemia; PYU(all): pyuria; RF: azotemia without pyuria; RF-PYU:
azotemia with pyuria; PYU: pyuria without azotemia.blood neutrophils have been reported to show a positive
correlation with NGAL concentration in serum but not
to be related to urine NGAL levels [29]. In this study,
the cases with higher blood leukocytes also had RF, and
therefore the presence of renal diseases may have influ-
enced the results. To investigate this, a comparative ana-
lysis of uNGAL concentration and blood WBC, as well
as neutrophils, across the non-RP and control groups
was carried out and this indicated that both WBC and
neutrophils were not significantly related to uNGAL
(data not shown). This implies that the concentration of
uNGAL is affected significantly by urinary tract diseases.
An increased uNGAL level has been reported to be an
early diagnosis indicator of urinary tract infection [30];
additionally, white blood cells in urine have been found
to be correlated with an increase in uNGAL concentra-
tion [31]. Consistent with the above, in the present
study, the uNGAL concentration in dogs with pyuria
(median: 15.35 ng/ml) was found to be significantly
higher than that in the control group (3.92 ng/ml),
which indicates that pyuria indeed increases the level of
uNGAL. Moreover, among the three forms, only the di-
meric uNGAL was associated with urine WBC; the di-
meric form of NGAL appears to be the major form of
uNGAL present in pyuria patients. An increase in the
dimeric form of uNGAL may be a useful way of differen-
tiating disease from kidney origin, where there is secre-
tion of monomeric NGAL.
The appearance of the uNGAL/MMP-9 complex was
found to be related in the present study to the presence
of increased creatinine, proteinuira, and increased num-
bers of urine leukocytes. The uNGAL/MMP-9 complex
has been reported to be related to the presence of cyst-
itis in children [31], but in this study, the uNGAL/
MMP-9 complex appeared not only to be present in
samples from the PYU groups but also in samples from
the RF without PYU group. Furthermore, the RF-PYU
groups had a higher proportion of uNGAL/MMP9-com-
plex than the PYU alone group. Inflammation has been
shown to stimulate the expression of MMP-9 [32], and,
in the present study, the cases with renal failure also had
higher leukocytes counts, and therefore the increase in
the presence of the uNGAL MMP9 complex in the renal
failure group seems rational. Based on the above find-
ings, the role that the uNGAL/MMP9 complex plays in
non-renal diseases needs to be investigated further.
In this study, a no-RP group was included to evaluate
the possible contribution of other diseases to the
uNGAL increase and this preliminary analysis showed
that uNGAL does not seem to be affected by other dis-
eases. However, the RF group was based on azotemia; as
a result, prerenal factors that contribute to any tubular
injury and were responsible for the elevation of uNGAL,
cannot be excluded.
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centrations is limited, it has been shown that, among
humans, the cut-off point for uNGAL in AKI patients
(50 to213 ng/mL) is higher than that in UTI patients (20
ng/mL) [30]. However, in dogs, despite higher uNGAL
levels being found in AKI cases, the increase of uNGAL
is not significant between the AKI cases and the cases
with pyuria. The possible reasons may be as follows.
First, our definition of AKI is based on the level of
serum creatinine, which is known to increase later than
uNGAL [33], this might have led to missing the peak
uNGAL level. Second, AKI can also be defined as a rise
in creatinine level from baseline; however without know-
ing the baseline of serum creatinine level for each case,
even though the serum creatinine concentration might
be within normal range, the possibility of renal injury
being responsible for any rise in uNGAL among PYU
cases cannot be ruled out.
Conclusions
Our results indicate that urinary NGAL concentration
alone does not seem to be able to differentiate the vari-
ous different types of urinary diseases, nevertheless, both
ELISA and Western blot approaches can be used to ex-
plore the changes in uNGAL and a combination of these
approaches seems to be a promising way of evaluating
urinary diseases. Thus, while an increase in uNGAL can
imply urinary abnormality, a simultaneous differential
analysis of the molecular forms of NGAL present in
urine is needed in order to understand comprehensively
the origin of the various forms of uNGAL.
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